ENPP1-blocking nanobody

The ENPP1-blocking nanobody is a novel therapeutic agent designed to inhibit the enzyme ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). ENPP1 is a cell-surface protein that hydrolyzes 2’3’-cyclic GMP-AMP (cGAMP), a critical activator of the Stimulator of Interferon Genes (STING) pathway. By blocking ENPP1 activity, the nanobody prevents the degradation of extracellular cGAMP, thereby promoting STING signaling in both tumor cells and immune cells like macrophages. This activation leads to increased T-cell infiltration, enhanced antigen presentation, and a more robust anti-tumor immune response. Preclinical research, particularly from the Moffitt Cancer Center, has demonstrated that this nanobody can overcome resistance to PARP inhibitors and anti-PD-1 therapy in homologous recombination-deficient (HRD) breast cancer models, suggesting a potent role for ENPP1 inhibition in combination cancer therapies.

Other names

ectonucleotide pyrophosphatase/phosphodiesterase 1 blocking nanobodyNb-ENPP1Nb-ENPP-1Nb-ENPP 1ENPP1 nanobodyENPP-1 nanobodyENPP 1 nanobody